Quote of the day and some no nonsense words

We do not see the things as they are. We see the things as we are.
Anais Nin

This is an extension of "Beauty is in the eye of the beholder". We are pre-programmed to see, to understand the world and everything around us. It was eye-opening when you ask a child what he see, and he answer "I know you want me to say the sign +, but all i see is 2 matchsticks one on top of another." We adapt everything through our experience, and we limit ourselves because of this. What is the solution? Every morning see the world as it is your first day here, on Earth. It is not easy, you will need a bit of practice, but is doable. Try it for a while. And you will change. You will become someone else. Something else. Outside any classification. Don't think, just do it!

* NucAla is the new hope in asthma treatment. The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Asthma is a chronic disease that causes inflammation in the airways of the lungs. During an asthma attack, airways become narrow making it hard to breathe. Severe asthma attacks can lead to asthma-related hospitalizations because these attacks can be serious and even life-threatening. According to the Centers for Disease Control and Prevention, as of 2013, more than 22 million people in the U.S. have asthma, and there are more than 400,000 asthma-related hospitalizations each year. “This approval offers patients with severe asthma an additional therapy when current treatments cannot maintain adequate control of their asthma,” said Badrul Chowdhury, M.D., Ph.D., director of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research. Nucala is administered once every four weeks by subcutaneous injection by a health care professional into the upper arm, thigh, or abdomen. Nucala is a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells. Nucala reduces severe asthma attacks by reducing the levels of blood eosinophils- a type of white blood cell that contributes to the development of asthma. The safety and efficacy of Nucala were established in three double-blind, randomized, placebo‑controlled trials in patients with severe asthma on currently available therapies. Nucala or a placebo was administered to patients every four weeks as an add-on asthma treatment. Compared with placebo, patients with severe asthma receiving Nucala had fewer exacerbations requiring hospitalization and/or emergency department visits, and a longer time to the first exacerbation. In addition, patients with severe asthma receiving Nucala experienced greater reductions in their daily maintenance oral corticosteroid dose, while maintaining asthma control compared with patients receiving placebo. Treatment with mepolizumab did not result in a significant improvement in lung function, as measured by the volume of air exhaled by patients in one second. The most common side effects of Nucala include headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and weakness (fatigue). Hypersensitivity reactions can occur within hours or days of being treated with Nucala, including swelling of the face, mouth, and tongue; fainting, dizziness, or lightheadedness; hives; breathing problems and rash. Herpes zoster infections have occurred in patients receiving Nucala. Herpes zoster is the virus that causes shingles. Nucala is made by GlaxoSmithKline, in Research Triangle Park, North Carolina. The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

** Did you heard about HeroX.com? HeroX was co-founded in 2013 by XPRIZE founder Peter Diamandis, challenge designer Emily Fowler and entrepreneur Christian Cotichini as a means to democratize the innovation model of XPRIZE. HeroX exists to enable anyone, anywhere in the world, to create a challenge that addresses any problem or opportunity, build a community around that challenge and activate the circumstances that can lead to a breakthrough innovation. This innovation model has existed for centuries. The Ansari XPRIZE was inspired by the 1927 Orteig Prize, in which Charles Lindbergh crossed the Atlantic in the Spirit of St. Louis. The $25,000 prize had been offered by hotelier Raymond Orteig to spur tourism. Lindbergh's flight lead to a boom in air travel the world over. A similar challenge had launched 200 years earlier with the 1716 Longitude Prize, which sought a technology to more accurately measure longitude at sea. Nearly 60 years later, a British clockmaker named John Harrison invented the chronometer, which spurred Trans-Atlantic migration on a massive scale. In 1795, Napoleon offered a 12,000 franc prize for a better method of preserving food, which was often spoiled by the time it reached the front lines of his armies. The breakthrough innovation to Napoleon's prize led to the creation of the canning industry. HeroX incentive prize challenges are designed to do the same — to harness the collective mind power of a community to innovate upon any problem or opportunity. Anyone can change the world. HeroX can help. The only question is, "What do you want to solve?"